ClinicalTrials.gg
CompletedNCT01617447Updated Apr 11, 2017Results posted

A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder

A Phase 3 interventional study of Placebo of Aripiprazole and Aripiprazole in Autistic Disorder, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 5 sites in Japan. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-04-11.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing aripiprazole in Autistic Disorder — none open to participants now, none under way, none of them phase 3. Aripiprazole · Autistic Disorder.

Enrollment
6th of 15
92 · median 81
Started
2012
with 1 other
Phase 3
7 of 15
none open now
Registered
12th of 15
by date
Lead sponsor
2 of 15
Otsuka Pharmaceutical Co., Ltd.

Among the 15 studies testing aripiprazole in Autistic Disorder, this one is the 6th largest by enrollment, is one of 2 that started in 2012, is one of 7 in phase 3, and was the 12th registered.

Autistic Disorder

1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

None of the 15 studies testing aripiprazole in Autistic Disorder is open now. The open studies under Autistic Disorder, anywhere →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing aripiprazole in Autistic Disorder as a file.
02

Study summary

The objective of this study is to investigate the efficacy and safety of aripiprazole orally administered over a period of 8 weeks in pediatric patients with Autistic Disorder

03

Conditions studied

  • Autistic Disorder

Browse trials for

Keywords

  • Autistic Disorder, children and adolescents
  • Aripiprazole
  • Double-blind
  • Randomized
  • children and adolescents
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient meets current diagnostic criteria for Autistic Disorder (defined in DSM-IV-TR) and also demonstrates behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these problems.
  • Inpatient or outpatient status
  • Others

Exclusion criteria

Exclusion Criteria:

  • The patient is currently diagnosed with another disorder on the autism spectrum in , including Asperger's, Rett's Disorder, PDD-NOS, Childhood Disintegrative Disorder, or Fragile-X Syndrome.
  • Patients who fall under a listed in the ABILIFY package insert
  • Others
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    administered orally once daily

    Drug: Placebo of Aripiprazole

  • Experimental
    Aripiprazole

    administered orally once daily

    Drug: Aripiprazole

Interventions

  • DrugPlacebo of Aripiprazole

    administered orally once daily

  • Flexibly dose administered orally once daily

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in the Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score

    The ABC-J Irritability subscale consists of 15 items. Each item scores range from 0 to 3: 0 = No problem, 1 = Mild aberrant behavior, 2 = Moderate aberrant behavior, and 3 = Severe aberrant behavior. Individual scores were summed, therefore, the overall score range was between 0-45. Higher scores represent worse condition.

    Time frame: baseline, 8 weeks after dosing

07

Results

Posted Apr 11, 2017

Participant flow

Participant flow — Overall Study
MilestoneAripiprazolePlacebo
Started4745
Completed4742
Not completed03
Withdrew: Adverse event01
Withdrew: Physician decision02

Outcome measures

PrimaryMean Change From Baseline in the Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score

The ABC-J Irritability subscale consists of 15 items. Each item scores range from 0 to 3: 0 = No problem, 1 = Mild aberrant behavior, 2 = Moderate aberrant behavior, and 3 = Severe aberrant behavior. Individual scores were summed, therefore, the overall score range was between 0-45. Higher scores represent worse condition.

Time frame:
baseline, 8 weeks after dosing
Reported as:
Mean · units on a scale
Mean Change From Baseline in the Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score
units on a scaleAripiprazolePlacebo
Mean Change From Baseline in the Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score-11.4 ± 1.3-7.5 ± 1.4

Adverse events

Collected over From the start date of investigational medicinal product (IMP) administration to date of the final examination (up to Week 8 at e hours after IMP administration). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole—0/47 (0%)39/47 (83%)
Placebo—1/45 (2.2%)32/45 (71.1%)
Most frequent serious events
Most frequent serious events
EventAripiprazolePlacebo
Heat illnessInjury, poisoning and procedural complications0/471/45
Most frequent other events
Showing 10 of 70
Most frequent other events
EventAripiprazolePlacebo
SomnolenceNervous system disorders24/474/45
NasopharyngitisInfections and infestations10/4711/45
Decreased appetiteMetabolism and nutrition disorders6/471/45
GastroenteritisInfections and infestations1/474/45
ContusionInjury, poisoning and procedural complications1/473/45
NauseaGastrointestinal disorders3/471/45
VomitingGastrointestinal disorders3/470/45
MalaiseGeneral disorders3/470/45
InfluenzaInfections and infestations2/472/45
InsomniaPsychiatric disorders0/472/45

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AripiprazolePlaceboTotal
<=18 years474592
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)AripiprazolePlaceboTotal
Mean10.3 ± 3.39.9 ± 3.110.1 ± 3.2
Sex: Female, Male
Sex: Female, Male(Participants)AripiprazolePlaceboTotal
Female8917
Male393675
Region of Enrollment
Region of Enrollment(participants)AripiprazolePlaceboTotal
Japan474592
08

Study locations

5 sites
  • Chubu Region, Japan
  • Chugoku Region, Japan
  • Kanto Region, Japan
  • Kinki Region, Japan
  • Kyushu Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2012
First posted
Jun 12, 2012
Start
Jul 2012
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Results first posted
Apr 11, 2017
Last update
Apr 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01617447
Responsible party
Sponsor
First posted
Jun 12, 2012
Start date
Jul 2012
Primary completion
Jun 2015
Completion
Jun 2015
Results posted
Apr 11, 2017
Last update
Apr 11, 2017

Study contacts

Kyoji Imaoka, Mr
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion